KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to $338.3 million.

  • Ionis Pharmaceuticals' Cash & Equivalents rose 1.12% to $338.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.3 million, marking a year-over-year increase of 1.12%. This contributed to the annual value of $242.1 million for FY2024, which is 39.37% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Cash & Equivalents stood at $338.3 million, which was up 13.80% from $297.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Cash & Equivalents registered a high of $869.2 million during Q4 2021, and its lowest value of $242.1 million during Q4 2024.
  • In the last 3 years, Ionis Pharmaceuticals' Cash & Equivalents had a median value of $334.6 million in 2024 and averaged $327.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 118.57% in 2021, then plummeted by 68.19% in 2022.
  • Ionis Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $869.2 million in 2021, then crashed by 68.19% to $276.5 million in 2022, then surged by 44.41% to $399.3 million in 2023, then plummeted by 39.37% to $242.1 million in 2024, then rose by 1.12% to $338.3 million in 2025.
  • Its Cash & Equivalents stands at $338.3 million for Q3 2025, versus $297.3 million for Q2 2025 and $264.2 million for Q1 2025.